RUNX2 mediated epithelial mesenchymal transition induced by TGF beta and Smad signaling promotes malignant progression in glioma.

ABSTRACT: RUNX2, a member of the RUNX transcription factor family, has been reported to promote epithelial-mesenchymal transition (EMT) in various malignancies, yet its role in glioma remains poorly understood. In this study, we systematically analyzed RUNX2 expression and clinical relevance in glioma using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets via the UALCAN web portal. Kaplan-Meier survival analyses and Wilcoxon rank-sum tests were employed to assess the prognostic significance of RUNX2. We further validated RUNX2 expression in glioma tissues and cell lines using RT-qPCR and Western blotting. Functional experiments, including CCK-8, wound healing, transwell invasion, and apoptosis assays, were conducted in U251 glioma cells with RUNX2 knockdown via siRNA. EM

SUBMITTER: Zhou P 

PROVIDER: S-EPMC12287292 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature